Sanifit to host webcast: Phase 2b CaLIPSO trial of SNF472

Monday 18 November at 11:00 ET /16:00 GMT / 17:00 CET
Sanifit will host a webcast on Monday November 18 at 11am ET / 5pm CET / 4pm GMT on the results of the international Phase 2b CaLIPSO study of lead candidate SNF472 in patients with end stage kidney disease (ESKD) on hemodialysis.

Joan Perelló, CEO and Alexander M. Gold, CMO of Sanifit will be joined by Dr. Glenn M. Chertow, Professor of Medicine (nephrology) and Health Research and Policy at Stanford University, on behalf of the CaLIPSO Steering Committee.

The study met its primary endpoint and demonstrated a reduction in coronary artery calcium (CAC) volume in patients treated with SNF472 as compared to patients receiving placebo over a 52-week period. Top line results will be presented at the Featured Science Session of the 2019 Scientific Sessions of the American Heart Association (AHA) this month.

To register, please contact a member of the team at Consilium Strategic Communications by email: sanifit@consilium-comms.com or tel: +44 (0)20 3709 5700.



Lundbeck Foundation gives its first coronavirus grant to trial with a known drug
26. March 2020
A 60-year-old’s muscles aren’t old at all
23. March 2020
The Lundbeck Foundation pledges DKK 30 million to coronavirus research
21. March 2020


Lundbeckfonden Ventures

Lundbeckfonden Emerge